You have 9 free searches left this month | to do more
Showing 1 - 25 of
1,099 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Available
  • Acute Lymphoblastic Leukemia (ALL)
  • (no location specified)
2021-09-21
Sep 21, 2021
M
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-19
Jan 19, 2022
M
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-12-29
Dec 29, 2021
G
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) - 2015
Completed
  • Philadelphia Positive Acute Lymphoblastic Leukemia
  • Stuttgart, Baden-Württemberg, Germany
  • +21 more
2022-01-10
Jan 10, 2022
U
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Recruiting
  • Acute Lymphoblastic Leukemia
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
2022-02-08
Feb 8, 2022
N
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations - 2011
Terminated
Has Results
  • CML
  • +2 more
  • Las Vegas, Nevada
  • +2 more
2021-04-28
Apr 28, 2021
U
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
Active, not recruiting
  • CML, Chronic Phase
  • +4 more
  • Chapel Hill, North Carolina
    UNC Hospital
2021-08-27
Aug 27, 2021
O
Venetoclax, Dasatinib, Prednisone, and Rituximab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Recurrent B Acute Lymphoblastic Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-12-27
Dec 27, 2021
M
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
Recruiting
  • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-01
Feb 1, 2022
M
ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML
Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Chicago, Illinois
  • +5 more
2021-12-27
Dec 27, 2021
N
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis - 2013
Completed
Has Results
  • Philadelphia Chromosome Positive CML
  • imatinib mesylate
  • Chicago, Illinois
  • +9 more
2021-06-03
Jun 3, 2021
B
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
Recruiting
  • Adult B Acute Lymphoblastic Leukemia
  • Philadelphia Chromosome Positive
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-10-11
Oct 11, 2021
M
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
Recruiting
  • Adult Acute Lymphoblastic Leukemia in Complete Remission
  • +3 more
  • Blinatumomab
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
2021-09-22
Sep 22, 2021
H
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt - 2020
Completed
  • Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase
  • Cairo, Egypt
    National Cancer Institute (NCI)
2021-02-22
Feb 22, 2021
M
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Recruiting
  • Acute Lymphoblastic Leukemia
  • Philadelphia Chromosome-Positive
  • Blinatumomab
  • +3 more
  • New York, New York
  • +1 more
2021-12-01
Dec 1, 2021
N
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) - 2019
Completed
Has Results
  • Chronic Myelogenous Leukemia
  • Eskisehir, Meselik, Turkey
  • +12 more
2020-08-18
Aug 18, 2020
N
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib - 2012
Terminated
Has Results
  • Chronic Myelogenous Leukemia - Chronic Phase
  • Los Angeles, California
  • +10 more
2021-07-26
Jul 26, 2021
M
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-20
Jan 20, 2022
M
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Recruiting
  • Blasts 5 Percent or More of Bone Marrow Nucleated Cells
  • +4 more
  • ADCT-602
  • Monrovia, California
  • +1 more
2022-01-25
Jan 25, 2022
C
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
Recruiting
  • CD19 Positive
  • +3 more
  • Blinatumomab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2021-05-17
May 17, 2021
M
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
Active, not recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
2021-05-05
May 5, 2021
I
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Active, not recruiting
  • Acute,Leukemia, Lymphoid
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
2021-02-08
Feb 8, 2021
N
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia - 2013
Completed
Has Results
  • Philadelphia Positive Chronic Myeloid Leukemia
  • +2 more
  • STI571 400 mg
  • STI571 600 mg
  • Boston, Massachusetts
  • +11 more
2021-07-01
Jul 1, 2021
M
Pegasys® in Patients With Myeloproliferative Diseases
Active, not recruiting
  • Myeloproliferative Disorders
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2021-11-17
Nov 17, 2021
M
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML - 2022
Completed
  • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-25
Mar 25, 2022